-
Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval
Wednesday, April 12, 2017 - 10:18am | 368Read More...BMO Capital Markets picked Neurocrine Biosciences, Inc.. (NASDAQ: NBIX) to Outperform expectations on Wednesday, one day after the the U.S. Food and Drug Administration approved the pharmaceutical company’s drug for the treatment of tardive dyskinesia, a neurological disorder. It was the...
-
Acadia Surges 22% After FDA Releases Briefing Documents
Monday, March 28, 2016 - 1:27pm | 348Read More...Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company that focuses on the development and commercialization of medicines for the treatment of neurological and central nervous system disorders, surged higher by more than 20 percent on Monday. According to Fierce...
